ChromaDex (NASDAQ:CDXC) Issues Quarterly Earnings Results

ChromaDex (NASDAQ:CDXCGet Rating) issued its quarterly earnings data on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02), Fidelity Earnings reports. ChromaDex had a negative net margin of 40.22% and a negative return on equity of 70.85%. During the same period last year, the firm posted ($0.12) earnings per share. ChromaDex updated its FY 2022 guidance to EPS.

Shares of CDXC stock traded up $0.05 during trading hours on Friday, reaching $1.69. The company had a trading volume of 528,822 shares, compared to its average volume of 443,491. The stock has a fifty day moving average of $2.21 and a 200-day moving average of $3.35. The company has a market capitalization of $115.48 million, a price-to-earnings ratio of -4.23 and a beta of 1.79. ChromaDex has a 12-month low of $1.51 and a 12-month high of $10.78.

Several brokerages have recently issued reports on CDXC. B. Riley decreased their price objective on ChromaDex from $8.00 to $6.00 in a report on Friday. StockNews.com started coverage on ChromaDex in a report on Thursday, March 31st. They issued a “hold” rating for the company. Roth Capital started coverage on ChromaDex in a report on Tuesday, March 8th. They issued a “buy” rating and a $7.00 price target for the company. Zacks Investment Research cut ChromaDex from a “hold” rating to a “sell” rating in a report on Monday, May 2nd. Finally, HC Wainwright reduced their price target on ChromaDex from $12.00 to $8.00 and set a “buy” rating for the company in a report on Monday, April 18th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $7.06.

In other ChromaDex news, CEO Robert N. Fried acquired 25,000 shares of the stock in a transaction that occurred on Wednesday, March 16th. The stock was bought at an average cost of $2.16 per share, for a total transaction of $54,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 11.84% of the stock is owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its holdings in shares of ChromaDex by 1.6% during the fourth quarter. BlackRock Inc. now owns 3,195,064 shares of the company’s stock worth $11,950,000 after purchasing an additional 51,383 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of ChromaDex by 9.5% during the first quarter. Vanguard Group Inc. now owns 2,781,437 shares of the company’s stock worth $6,842,000 after purchasing an additional 240,414 shares during the last quarter. State Street Corp grew its holdings in shares of ChromaDex by 1.2% during the fourth quarter. State Street Corp now owns 896,218 shares of the company’s stock worth $3,352,000 after purchasing an additional 10,855 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of ChromaDex by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 881,268 shares of the company’s stock worth $3,295,000 after purchasing an additional 17,054 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of ChromaDex by 22.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 431,126 shares of the company’s stock worth $1,613,000 after purchasing an additional 78,834 shares during the last quarter. Institutional investors own 29.64% of the company’s stock.

About ChromaDex (Get Rating)

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

Recommended Stories

Earnings History for ChromaDex (NASDAQ:CDXC)

Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.